Person:
Fernández de los Reyes, Irene

Profile Picture

Email Address

person.page.identifierURI

https://academica-e.unavarra.es/handle/2454/51403

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Fernández de los Reyes

First Name

Irene

person.page.departamento

Ciencias de la Salud

person.page.instituteName

ORCID

0000-0001-9762-7173

person.page.upna

812797

Name

Filters

20231
Reset filters

Settings

Author: Fernández de los Reyes, Irene × Subject: Colon cancer ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    PublicationOpen Access
    ZEB1 hypermethylation is associated with better prognosis in patients with colon cancer
    (BMC, 2023) Fernández de los Reyes, Irene; Gómez Dorronsoro, María Luisa; Monreal Santesteban, Iñaki; Fernández-Fernández, Agustín; Fraga, Mario; Azcue Sanromán, Pablo; Alonso, Laura; Fernández-Marlasca, Beatriz; Suárez Alecha, Javier; Córdoba Iturriagagoitia, Alicia; Guerrero Setas, David; Ciencias de la Salud; Osasun Zientziak; Universidad Pública de Navarra / Nafarroako Unibertsitate Publikoa
    Background: Colon cancer (CC) is a heterogeneous disease that is categorized into four Consensus Molecular Subtypes (CMS) according to gene expression. Patients with loco-regional CC (stages II/III) lack prognostic factors, making it essential to analyze new molecular markers that can delineate more aggressive tumors. Aberrant methylation of genes that are essential in crucial mechanisms such as epithelial mesenchymal transition (EMT) contributes to tumor progression in CC. We evaluate the presence of hyper- and hypomethylation in subrogate IHC markers used for CMS classification (CDX2, FRMD6, HTR2B, ZEB1) of 144 stage II/III patients and CC cell lines by pyrosequencing. ZEB1 expression was also studied in control and shRNA-silenced CC cell lines and in paired normal tissue/tumors by quantitative PCR. The pattern of ZEB1 staining was also analyzed in methylated/unmethylated tumors by immunohistochemistry. Results: We describe for the first time the hypermethylation of ZEB1 gene and the hypomethylation of the FRMD6 gene in 32.6% and 50.9% of tumors, respectively. Additionally, we confirm the ZEB1 re-expression by epigenetic drugs in methylated cell lines. ZEB1 hypermethylation was more frequent in CMS1 patients and, more importantly, was a good prognostic factor related to disease-free survival (p = 0.015) and overall survival (p = 0.006) in our patient series, independently of other significant clinical parameters such as patient age, stage, lymph node involvement, and blood vessel and perineural invasión. Conclusions: Aberrant methylation is present in the subrogate genes used for CMS classification. Our results are the first evidence that ZEB1 is hypermethylated in CC and that this alteration is an independent factor of good prognosis.